0
Scientific Articles   |    
Recombinant Human BMP-2 and Allograft Compared with Autogenous Bone Graft for Reconstruction of Diaphyseal Tibial Fractures with Cortical DefectsA Randomized, Controlled Trial
Alan L. Jones, MD1; Robert W. Bucholz, MD2; Michael J. Bosse, MD3; Sohail K. Mirza, MD, MPH4; Thomas R. Lyon, MD5; Lawrence X. Webb, MD6; Andrew N. Pollak, MD7; Jane Davis Golden, PT, MHP8; Alexandre Valentin-Opran, MD8
1 Orthopaedic Trauma Association of North Texas, 3600 Gaston Avenue, Barnett Tower, Suite 1101, Dallas, TX 75246
2 Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235
3 Department of Orthopaedic Surgery, Carolinas Medical Center, P.O. Box 32861, Charlotte, NC 28232
4 Department of Orthopaedics, Harborview Medical Center, University of Washington, 325 Ninth Avenue, Seattle, WA 98104
5 Department of Trauma Services, Lutheran Medical Center, 150 55th Street, Brooklyn, NY 11220
6 Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157
7 Department of Orthopaedics, University of Maryland School of Medicine, 22 South Greene Street, Suite T3R54, Baltimore, MD 21201
8 Wyeth Research, 87 CambridgePark Drive, Cambridge, MA 02140. E-mail address for J.D. Golden: jdavis@wyeth.com
View Disclosures and Other Information
In support of their research for or preparation of this manuscript, one or more of the authors received grants or outside funding from Wyeth Research. None of the authors received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. A commercial entity (Wyeth Research) paid or directed, or agreed to pay or direct, benefits to a research fund, foundation, educational institution, or other charitable or nonprofit organization with which seven of the authors are affiliated or associated. Two other authors are salaried employees of Wyeth Research.
A commentary is available with the electronic versions of this article, on our web site (www.jbjs.org) and on our quarterly CD-ROM (call our subscription department, at 781-449-9780, to order the CD-ROM).
Investigation performed at University of Texas Southwestern Medical Center, Dallas, Texas; University of Maryland School of Medicine, Baltimore, Maryland; Carolinas Medical Center, Charlotte, North Carolina; Harborview Medical Center, Seattle, Washington; Lutheran Medical Center, Brooklyn, New York; and Wake Forest School of Medicine Medical Center, Winston-Salem, North Carolina

The Journal of Bone and Joint Surgery, Incorporated
J Bone Joint Surg Am, 2006 Jul 01;88(7):1431-1441. doi: 10.2106/JBJS.E.00381
5 Recommendations (Recommend) | 3 Comments | Saved by 3 Users Save Case

Abstract

Background: Currently, the treatment of diaphyseal tibial fractures associated with substantial bone loss often involves autogenous bone-grafting as part of a staged reconstruction. Although this technique results in high healing rates, the donor-site morbidity and potentially limited supply of suitable autogenous bone in some patients are commonly recognized drawbacks. The purpose of the present study was to investigate the benefit and safety of the osteoinductive protein recombinant human bone morphogenetic protein-2 (rhBMP-2) when implanted on an absorbable collagen sponge in combination with freeze-dried cancellous allograft.

Methods: Adult patients with a tibial diaphyseal fracture and a residual cortical defect were randomly assigned to receive either autogenous bone graft or allograft (cancellous bone chips) for staged reconstruction of the tibial defect. Patients in the allograft group also received an onlay application of rhBMP-2 on an absorbable collagen sponge. The clinical evaluation of fracture-healing included an assessment of pain with full weight-bearing and fracture-site tenderness. The Short Musculoskeletal Function Assessment (SMFA) was administered before and after treatment. Radiographs were used to document union, the presence of extracortical bridging callus, and incorporation of the bone-graft material.

Results: Fifteen patients were enrolled in each group. The mean length of the defect was 4 cm (range, 1 to 7 cm). Ten patients in the autograft group and thirteen patients in the rhBMP-2/allograft group had healing without further intervention. The mean estimated blood loss was significantly less in the rhBMP-2/allograft group. Improvement in the SMFA scores was comparable between the groups. No patient in the rhBMP-2/allograft group had development of antibodies to BMP-2; one patient had development of transient antibodies to bovine type-I collagen.

Conclusions: The present study suggests that rhBMP-2/allograft is safe and as effective as traditional autogenous bone-grafting for the treatment of tibial fractures associated with extensive traumatic diaphyseal bone loss.

Level of Evidence: Therapeutic Level II. See Instructions to Authors for a complete description of levels of evidence.

Figures in this Article
    Sign In to Your Personal ProfileSign In To Access Full Content
    Not a Subscriber?
    Get online access for 30 days for $35
    New to JBJS?
    Sign up for a full subscription to both the print and online editions
    Register for a FREE limited account to get full access to all CME activities, to comment on public articles, or to sign up for alerts.
    Register for a FREE limited account to get full access to all CME activities
    Have a subscription to the print edition?
    Current subscribers to The Journal of Bone & Joint Surgery in either the print or quarterly DVD formats receive free online access to JBJS.org.
    Forgot your password?
    Enter your username and email address. We'll send you a reminder to the email address on record.

     
    Forgot your username or need assistance? Please contact customer service at subs@jbjs.org. If your access is provided
    by your institution, please contact you librarian or administrator for username and password information. Institutional
    administrators, to reset your institution's master username or password, please contact subs@jbjs.org

    References

    Accreditation Statement
    These activities have been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Academy of Orthopaedic Surgeons and The Journal of Bone and Joint Surgery, Inc. The American Academy of Orthopaedic Surgeons is accredited by the ACCME to provide continuing medical education for physicians.
    CME Activities Associated with This Article
    Submit a Comment
    Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
    Comments are moderated and will appear on the site at the discretion of JBJS editorial staff.

    * = Required Field
    (if multiple authors, separate names by comma)
    Example: John Doe





    Jane Davis Golden, PT, MHP
    Posted on January 18, 2008
    Ms. Davis Golden et al. respond to Dr. Krause et al.
    Wyeth Research, Cambridge, MA

    Dr Krause and colleagues are correct in the fact that the local and systemic exposure in patients treated with rhBMP-2 is very short; animal studies have shown the systemic half-life of rhBMP-2 to be between 7 to 16 minutes and the local mean residence time of rhBMP-2 when implanted on its collagen carrier is 8 days. BMP-2 and BMP-2 receptors are expressed in a variety of tissues and cell types, including both normal and malignant cells. BMPs (as well as other proteins) have been shown to be expressed in many epithelial-derived neoplasms including prostate, pancreas, breast, etc. To our knowledge,however, there are no data demonstrating that BMPs induce malignant transformation of cells.

    Data regarding the effect of exogenous BMP-2 on malignant cells are conflicting; some publications suggest that BMP-2 may stimulate the proliferation of malignant cells(1,2), while the majority of studies have shown that BMP-2 inhibits or has no effect on the proliferation of malignant cells(3-8). Because of the potential risk of stimulating existing cancer growth, rhBMP-2 should not be implanted at the site of a resected tumor and patients who have an active malignancy or are undergoing treatment for malignancy should not be treated with rhBMP-2.

    rhBMP-2 has been the subject of 3 separate reviews by the Food and Drug Administration, resulting in approvals for spinal fusion, tibial fracture, and oral/maxillofacial indications in the United States (with further reviews/approvals still pending). In addition, rhBMP-2 has been reviewed by regulatory authorities outside of the United States and is approved for use in more than 20 other countries. It is estimated that rhBMP-2 has now been used in more than 500,000 patients. In the 5 years since its first approval, Wyeth and Medtronic have continued to monitor reports from health care professionals and other sources and there have been no reports of malignancies of bone related to the commercial use of rhBMP-2.

    Wyeth and its marketing partner, Medtronic, routinely monitor cancer reports in randomized clinical trials and long-term trial extensions. As of September 2007, 23 malignancies (excluding non-melanoma skin cancers) were observed among 2043 patients treated with rhBMP-2 over 4498 patient- years of follow-up (mean follow-up 2.2 years post-treatment). Of note, none of these reports involved malignancies of bone. To interpret these data, the standardized incidence ratio (SIR) for malignancy was determined. The SIR, which is a proxy for relative risk, compares observed and expected number of events. The expected number was calculated using reference rates from the US Surveillance, Epidemiology and End Results (SEER)(9) cancer registry applied to the exposure time from the rhBMP-2 studies, adjusting for age, gender and race to specifically reflect the population exposed to rhBMP-2. The SIR was 0.9 (95% CI: 0.6 - 1.3). This indicates that the frequency of malignancies observed in the patients treated with rhBMP-2 in clinical studies is consistent with what one would expect for the general population of similar demographic makeup.

    Wyeth and Medtronic will continue with active pharmacovigilence of this important issue.

    References:

    1. Langenfeld EM, Calvano SE, Abou-Noukta F, Lowry S Amenta P, Langenfeld J. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small lung carcinoma and stimulates tumor growth of A549 cells. Carcinogenesis. 24 (9): 1445-54, 2003 Sep.

    2. Kleff J, Muruyama H, Ishiwata T, Sawhney H, Friess H, Buchler M, Kore M. Bone morphogenetic protein-2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology. 116 (5): 1202-16, 1999 May.

    3. Soda H, Raymond E, Sharma S, Lawrence R, Cerna C, Gomez L, Timony GA, Von Hoff DD, Izbicka E. Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anti- Cancer Drugs. 9:327-331, 1998.

    4. Orui H, Imaizumi S, Ogino T, Motoyama T. Effects of bone morphogenetic protein-2 on human tumor cell growth and differentiation: a preliminary report. J Orthop Sci 5:600-4, 2000.

    5. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 444(7120):761-5, 2006.

    6. Kumagai T, Shimizu T, Takeda K. Bone morphogenetic protein-2 suppresses invasiveness of TSU-Pr1 cells with the inhibition of MMP-9 secretion. Anticancer Res. 26(1A):293-8, 2006.

    7. Wen XZ, Miyake S, Akiyama Y, Yuasa Y. BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun. 316(1):100-6, 2004.

    8. Ghosh-Choudhury N, Woodruff K, Qi W, Celeste A, Abboud SL, Ghosh Choudhury G. Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. Biochem Biophys Res Commun. 272(3):705-11, 2000.

    9. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 13 Regs Limited -Use, Nov 2006 Sub (1992-2004) - Linked To County Attributes - Total U.S., 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.

    Fabian Krause
    Posted on November 16, 2007
    Implication of BMPs in the development of tumors.
    Department of Orthopedic Surgery, Inselspital Berne, Switzerland

    To The Editor:

    We congratulate the authors of this excellent study demonstrating the equivalence in efficacy and safety of autograft and allograft/BMP in the reconstruction of tibial cortical defects. Although safety has been shown in the short-term and no incidents of longterm adverse effects have been reported to our knowledge, concerns still arise from reports on an association of BMP to primary and secondary bone tumors (1,2,3). Aberrations in BMPs signaling have also been identified in various neoplasms(3).

    Locally applied BMPs will be biologically active over only a short period of time, and bone is a tissue with very slow turnover. The risk of locally inducing a bone tumor may seem negligibly low. Still, it is an unphysiological and aggressive stimulus the longterm implications of which remain to be seen.

    Because of their experience in treating patients with BMP, we would like to pose the following questions to the authors:

    - Have they seen any development of primary or secondary (bone) tumors in patients treated with BMP?

    - Do they continue to follow-up patients that received BMP for tumor-onset?

    - Is there a need for a comparative study regarding the prevalence of tumor-onset in patients treated with and without BMP?

    The authors did not receive any outside funding or grants in support of their research for or preparation of this work. Neither they nor a member of their immediate families received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, division, center, clinical practice, or other charitable or nonprofit organization with which the authors, or a member of their immediate families, are affiliated or associated.

    References:

    1. Weiss KR, Cooper GM, Jadlowiec JA, McGough RL 3rd, Huard J. VEGF and BMP expression in mouse osteosarcoma cells. Clin Orthop Relat Res. 2006 Sep;450:111-7.

    2. Ye L, Lewis-Russell JM, Kyanaston HG, Jiang WG. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol. 2007 Oct;22(10):1129-47.

    3. Yoshikawa H, Nakase T, Myoui A, Ueda T. Bone morphogenetic proteins in bone tumors. J Orthop Sci. 2004;9(3):334-40.

    Related Content
    The Journal of Bone & Joint Surgery
    JBJS Case Connector
    Topic Collections
    Related Audio and Videos
    PubMed Articles
    Guidelines
    Results provided by:
    PubMed
    Clinical Trials
    Readers of This Also Read...
    JBJS Jobs